Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study

Aim: To evaluate the outcomes of combined intravitreal triamcinolone (IVTA) and photodynamic therapy (PDT) with verteporfin in the treatment of subfoveal choroidal neovascularisation (CNV) caused by age related macular degeneration (AMD). Methods: 48 eyes from 48 patients with subfoveal CNV caused b...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of ophthalmology Vol. 90; no. 3; pp. 337 - 341
Main Authors Chan, W-M, Lai, T Y Y, Wong, A L, Tong, J-P, Liu, D T L, Lam, D S C
Format Journal Article
LanguageEnglish
Published BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.03.2006
BMJ
BMJ Publishing Group LTD
BMJ Group
Subjects
AMD
CNV
IOP
PDT
RPE
Online AccessGet full text

Cover

Loading…
More Information
Summary:Aim: To evaluate the outcomes of combined intravitreal triamcinolone (IVTA) and photodynamic therapy (PDT) with verteporfin in the treatment of subfoveal choroidal neovascularisation (CNV) caused by age related macular degeneration (AMD). Methods: 48 eyes from 48 patients with subfoveal CNV caused by AMD were prospective recruited, with 24 eyes treated with combined PDT with IVTA and compared with a control group of 24 eyes which received PDT monotherapy. In the combined treatment group, IVTA was performed immediately after PDT as an outpatient procedure. The mean number of treatments, mean logMAR best corrected visual acuity (BCVA), mean line of visual acuity changes, and proportion of patients without moderate visual loss at 1 year were compared between the combined and monotherapy groups. Results: At 1 year the logMAR BCVA for the PDT with IVTA group changed from 0.88 to 0.95 (p = 0.32 compared with baseline), whereas the logMAR BCVA for the monotherapy group reduced from 0.74 to 1.09 (p<0.001 compared with baseline). A significantly higher proportion of patients who had PDT with IVTA did not develop moderate visual loss at 1 year compared with the monotherapy group (70.8% and 33.3% respectively, p = 0.009). Eyes which had combined treatment had significantly fewer lines lost compared with monotherapy alone (0.7 and 3.5 lines respectively, p = 0.015). Subgroup analysis showed that PDT with IVTA is effective in preventing visual loss in both predominately classic and occult CNV groups. The mean number of treatments for the combined and monotherapy groups was 1.5 and 1.96 respectively (p = 0.076). Conclusions: Combined PDT with IVTA appeared more effective statistically at 12 months for stabilisation of vision (<3 logMAR lines change) compared with PDT monotherapy. Further randomised control trials might be justified to conclude the efficacy of PDT with IVTA.
Bibliography:local:0900337
istex:61F581AF6BB9FA43A97A39496785C2EE90B13C86
href:bjophthalmol-90-337.pdf
Correspondence to: Professor Wai-Man Chan Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, 147K Argyle Street, Hong Kong; cwm6373@netvigator.com
ark:/67375/NVC-6ZRGXS51-L
PMID:16488958
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0007-1161
1468-2079
DOI:10.1136/bjo.2005.081299